Answers are grounded in this paper and cite their sources.
Preclinical investigation reveals targeted drug delivery via aptide-conjugated liposomes in glioma models, suggesting an efficient therapeutic platform.
Aptides, developed by our laboratory, are a novel class of high-affinity peptides. Here, we describe the conjugation of an aptide targeting extra-domain B (EDB) of tumor-associated fibronectin to drug-containing liposomes and explore the potential of these aptide-conjugated liposomes as a robust and efficient targeted drug-delivery system for glioma therapy.
No takes yet. Share an insight, caveat, or question.
Saw et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: